ARM Innovation Hub
Cambridgeand mid banner advertisement
Advertisement: partnersand mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement: CJBS mid banner
Advertisement: Excalibur Healthcare mid banner
Barr Ellison Solicitors – commercial property
Advertisement mid banner S-Tech 1
Advertisement: Simpsons Creative mid banner
Advertisement: RSM mid banner
Advertisement: SATAVIA mid banner
Advertisement: Cambridge Network mid banner
Mid banner advertisement: BDO
Advertisement: Bar Ellison mid banner property
Advertisement: Kao Data Centre mid banner
Advertisement: Mogrify mid banner
Advertisement: Birketts mid banner
Advertisement: EBCam mid banner
18 November, 2021 - 11:17 By Tony Quested

Diabetes pioneer raises almost double funding target

MedTech firm, Glyconics© has secured £1.5 million in an oversubscribed Enterprise Investment Scheme (EIS) funding round ahead of a series A next year.

The diagnostics startup – with offices in Cambridge, Norwich and Basingstoke – raised well over the original £850k target in a round led by investment platform Wealth Club and existing backers, Deepbridge Capital and Boundary Capital. 

Demand from Wealth Club private investors and angel investors pushed the total amount to almost double the original target.

The raise will fund a large-scale trial programme of Glyconics©’ game-changing point-of-care diabetes screening tool, Glyconics-SX™, prior to applying for regulatory approval and CE marking.  

The non-invasive handheld device exploits the use of miniaturised infra-red spectrometry for the early diagnosis of diabetes – detecting biomarker changes in a patient’s fingernail within seconds and without the need for single use plastics. 

Diabetes is a global epidemic and public health challenge, killing more people than breast cancer and prostate cancer combined every year. It is a major cause of severe complications leading to blindness, kidney failure, heart attack, stroke and lower limb amputation, and the World Health Organisation projects it will be the seventh leading cause of death by 2030. 

Early detection is key to long-term management of the condition and increased life expectancy. However, screening currently depends on blood or urine tests which require plastic disposables with related processing, logistics and costly resources; these have been heavily criticised for producing false positives or failing to detect the disease. 

News of the oversubscribed round comes hot on the heels of the company employing internationally renowned diabetes expert, Dr Päivi Paldánius to be the company’s first chief medical officer as the team ramps up to progress to the next clinical phase. 

Glyconics has already been awarded an EU Seal of Excellence certificate for its technology and was listed as one of the ‘80 standout European start-up pioneers driving seismic change in the post-pandemic world’ by The FT-backed innovation website,

Dr Kam Pooni, CEO of Glyconics, said: “Glyconics offers a transformational, cost-efficient, rapid and non-invasive approach to diabetes screening – and it is testament to this pioneering device and all at Team Glyconics that this raise was so significantly over-subscribed. 

“We are delighted to be continuing with our existing investors and, of course, welcome our new backers from Wealth Club and other private investors to the fold.”

Newsletter Subscription

Stay informed of the latest news and features